Genetic tailoring of pharmacotherapy in heart failure: Optimize the old, while we wait for something new

Journal of Cardiac Failure

Volumn 18, Issue 4, 2012, Pages 338-349

  Talameh, Jasmine A ^a   McLeod, Howard L ^a,b   Adams Jr , Kirkwood F ^a,b   Patterson, J Herbert ^a,b  

^a UNC Hamner Institute for Drug Safety Sciences   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

ACE inhibitor; beta blocker; Heart failure; pharmacogenetic; pharmacogenomic; polymorphism; variant

Indexed keywords

ADENYLATE CYCLASE; ALDOSTERONE; ALPHA 2C ADRENERGIC RECEPTOR; BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUCINDOLOL; CAPTOPRIL; CARVEDILOL; CYCLIC AMP; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; G PROTEIN COUPLED RECEPTOR KINASE 5; GLUTAMINE; LEUCINE; LISINOPRIL; MALONALDEHYDE; METOPROLOL; PLACEBO; SERINE;

AFRICAN AMERICAN; ALLELE; CHROMOSOME 10Q; DESENSITIZATION; DRUG MEGADOSE; ENZYME ACTIVITY; GENE DELETION; GENE FREQUENCY; GENE INSERTION; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART RATE; HOMOZYGOSITY; HUMAN; IN VITRO STUDY; INTRON; MEAN ARTERIAL PRESSURE; MEDLINE; MORTALITY; NONISCHEMIC CARDIOMYOPATHY; PHARMACOGENETICS; PRIORITY JOURNAL; RACE DIFFERENCE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SURVIVAL; SYSTEMATIC REVIEW;

ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; GENE DELETION; GENETIC VARIATION; HEART FAILURE; HUMANS; INDIVIDUALIZED MEDICINE; METOPROLOL; MUTAGENESIS, INSERTIONAL; RECEPTORS, ADRENERGIC, BETA-1; TREATMENT OUTCOME;

EID: 84859214730     PISSN: 10719164     EISSN: 15328414     Source Type: Journal    
DOI: 10.1016/j.cardfail.2012.01.002     Document Type: Review

References (82)

1. Heart Failure Society of America Heart Failure Society of America (HFSA) practice guidelines. HFSA guidelines for management of patients with heart failure caused by left ventricular systolic dysfunction - pharmacological approaches J Card Fail 5 1999 357 382
2. K.F. Adams Development and implementation of heart failure practice guidelines D.L. Mann, Heart failure: a companion to Braunwald's heart disease 2nd ed. 2011 Saunders Philadelphia
3. K.F. Adams Beta-blockers in heart failure: how far have we progressed? Postgrad Med 112 5 Suppl 2002 7 15
4. R.J. MacFadyen, A.F. Lee, J.J. Morton, S.D. Pringle, and A.D. Struthers How often are angiotensin II and aldosterone concentrations raised during chronic ACE inhibitor treatment in cardiac failure? Heart 82 1999 57 61
5. Z.H. Israili, and W.D. Hall Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology Ann Intern Med 117 1992 234 242
6. M. Metra, R. Giubbini, S. Nodari, E. Boldi, M.G. Modena, and L. dei Cas Differential effects of beta-blockers in patients with heart failure: A prospective, randomized, double-blind comparison of the long-term effects of metoprolol versus carvedilol Circulation 102 2000 546 551
7. J. Lindenfeld, N.M. Albert, J.P. Boehmer, S.P. Collins, J.A. Ezekowitz Heart Failure Society of America HFSA 2010 comprehensive heart failure practice guideline J Card Fail 16 2010 e1 e194
8. B. Andersson, and C. Sylven The DD genotype of the angiotensin-converting enzyme gene is associated with increased mortality in idiopathic heart failure J Am Coll Cardiol 28 1996 162 167
9. S.B. Liggett, L.E. Wagoner, L.L. Craft, R.W. Hornung, B.D. Hoit, and T.C. McIntosh The Ile164 beta2-adrenergic receptor polymorphism adversely affects the outcome of congestive heart failure J Clin Invest 102 1998 1534 1539
10. D.M. McNamara, R. Holubkov, L. Postava, R. Ramani, K. Janosko, and M. Mathier Effect of the Asp298 variant of endothelial nitric oxide synthase on survival for patients with congestive heart failure Circulation 107 2003 1598 1602
11. A.C. Morrison, J.F. Felix, L.A. Cupples, N.L. Glazer, L.R. Loehr, and A. Dehghan Genomic variation associated with mortality among adults of European and African ancestry with heart failure: the cohorts for heart and aging research in genomic epidemiology consortium Circ Cardiovasc Genet 3 2010 248 255
12. R. Troncoso, F. Moraga, M. Chiong, J. Roldan, R. Bravo, and R. Valenzuela Gln(27)→Glubeta(2)-adrenergic receptor polymorphism in heart failure patients: differential clinical and oxidative response to carvedilol Basic Clin Pharmacol Toxicol 104 2009 374 378
13. S. Cresci, R.J. Kelly, T.P. Cappola, A. Diwan, D. Dries, and S.L. Kardia Clinical and genetic modifiers of long-term survival in heart failure J Am Coll Cardiol 54 2009 432 444
14. S.B. Liggett, J. Mialet-Perez, S. Thaneemit-Chen, S.A. Weber, S.M. Greene, and D. Hodne A polymorphism within a conserved beta(1)-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure Proc Natl Acad Sci U S A 103 2006 11288 11293
15. M.R. Taylor, D. Slavov, K. Humphrey, L. Zhao, J. Cockroft, and X. Zhu Pharmacogenetic effect of an endothelin-1 haplotype on response to bucindolol therapy in chronic heart failure Pharmacogenet Genomics 19 2009 35 43
16. M.R. Bristow, G.A. Murphy, H. Krause-Steinrauf, J.L. Anderson, J.F. Carlquist, and S. Thaneemit-Chen An alpha2C-adrenergic receptor polymorphism alters the norepinephrine-lowering effects and therapeutic response of the beta-blocker bucindolol in chronic heart failure Circ Heart Fail 3 2010 21 28
17. D.M. McNamara, R. Holubkov, K. Janosko, A. Palmer, J.J. Wang, and G.A. MacGowan Pharmacogenetic interactions between beta-blocker therapy and the angiotensin-converting enzyme deletion polymorphism in patients with congestive heart failure Circulation 103 2001 1644 1648
18. D.M. McNamara, R. Holubkov, L. Postava, K. Janosko, G.A. MacGowan, and M. Mathier Pharmacogenetic interactions between angiotensin-converting enzyme inhibitor therapy and the angiotensin-converting enzyme deletion polymorphism in patients with congestive heart failure J Am Coll Cardiol 44 2004 2019 2026
19. P. de Groote, N. Helbecque, N. Lamblin, X. Hermant, P. Amouyel, and C. Bauters Beta-adrenergic receptor blockade and the angiotensin-converting enzyme deletion polymorphism in patients with chronic heart failure Eur J Heart Fail 6 2004 17 21
20. T. Frielle, S. Collins, K.W. Daniel, M.G. Caron, R.J. Lefkowitz, and B.K. Kobilka Cloning of the cDNA for the human beta 1-adrenergic receptor Proc Natl Acad Sci U S A 84 1987 7920 7924
21. M.C. Levin, S. Marullo, O. Muntaner, B. Andersson, and Y. Magnusson The myocardium-protective Gly-49 variant of the beta 1-adrenergic receptor exhibits constitutive activity and increased desensitization and down-regulation J Biol Chem 277 2002 30429 30435
22. D.A. Rathz, K.M. Brown, L.A. Kramer, and S.B. Liggett Amino acid 49 polymorphisms of the human beta1-adrenergic receptor affect agonist-promoted trafficking J Cardiovasc Pharmacol 39 2002 155 160
23. D.L. Mann, R.L. Kent, B. Parsons, and G. Cooper 4th. Adrenergic effects on the biology of the adult mammalian cardiocyte Circulation 85 1992 790 804
24. S.G. Terra, K.K. Hamilton, D.F. Pauly, C.R. Lee, J.H. Patterson, and K.F. Adams Beta1-adrenergic receptor polymorphisms and left ventricular remodeling changes in response to beta-blocker therapy Pharmacogenet Genomics 15 2005 227 234
25. P. de Groote, N. Helbecque, N. Lamblin, X. Hermant, E. Mc Fadden, and C. Foucher-Hossein Association between beta-1 and beta-2 adrenergic receptor gene polymorphisms and the response to beta-blockade in patients with stable congestive heart failure Pharmacogenet Genomics 15 2005 137 142
26. S. Nonen, H. Okamoto, Y. Fujio, Y. Takemoto, M. Yoshiyama, and T. Hamaguchi Polymorphisms of norepinephrine transporter and adrenergic receptor alpha1D are associated with the response to beta-blockers in dilated cardiomyopathy Pharmacogenomics J 8 2008 78 84
27. B.D. Lowes, E.A. Gill, W.T. Abraham, J.R. Larrain, A.D. Robertson, and M.R. Bristow Effects of carvedilol on left ventricular mass, chamber geometry, and mitral regurgitation in chronic heart failure Am J Cardiol 83 1999 1201 1205
28. L. Chen, D. Meyers, G. Javorsky, D. Burstow, P. Lolekha, and M. Lucas Arg389Gly-beta1-adrenergic receptors determine improvement in left ventricular systolic function in nonischemic cardiomyopathy patients with heart failure after chronic treatment with carvedilol Pharmacogenet Genomics 17 2007 941 949
29. M. Borjesson, Y. Magnusson, A. Hjalmarson, and B. Andersson A novel polymorphism in the gene coding for the beta(1)-adrenergic receptor associated with survival in patients with heart failure Eur Heart J 21 2000 1853 1858
30. Y. Magnusson, M.C. Levin, R. Eggertsen, E. Nystrom, R. Mobini, and M. Schaufelberger Ser49Gly of beta1-adrenergic receptor is associated with effective beta-blocker dose in dilated cardiomyopathy Clin Pharmacol Ther 78 2005 221 231
31. A. Biolo, N. Clausell, K.G. Santos, R. Salvaro, P. Ashton-Prolla, and A. Borges Impact of beta1-adrenergic receptor polymorphisms on susceptibility to heart failure, arrhythmogenesis, prognosis, and response to beta-blocker therapy Am J Cardiol 102 2008 726 732
32. J.P. Ioannidis, E.E. Ntzani, T.A. Trikalinos, and D.G. Contopoulos-Ioannidis Replication validity of genetic association studies Nat Genet 29 2001 306 309
33. O.E. Brodde, and M.C. Michel Adrenergic and muscarinic receptors in the human heart Pharmacol Rev 51 1999 651 690
34. D.A. Mason, J.D. Moore, S.A. Green, and S.B. Liggett A gain-of-function polymorphism in a G-protein coupling domain of the human beta1-adrenergic receptor J Biol Chem 274 1999 12670 12674
35. J. Mialet Perez, D.A. Rathz, N.N. Petrashevskaya, H.S. Hahn, L.E. Wagoner, and A. Schwartz Beta 1-adrenergic receptor polymorphisms confer differential function and predisposition to heart failure Nat Med 9 2003 1300 1305
36. M. Luo, Y. Bi, and Y.X. Xu Effects of metoprolol on beta1 adrenergic receptor polymorphism and receptor density in urban Chinese patients with heart failure Chin Med J (Engl) 120 2007 1720 1723
37. H. Hu, H.Y. Jui, F.C. Hu, Y.H. Chen, L.P. Lai, and C.M. Lee Predictors of therapeutic response to beta-blockers in patients with heart failure in Taiwan J Formos Med Assoc 106 2007 641 648
38. M. Metra, L. Covolo, N. Pezzali, V. Zaca, S. Bugatti, and C. Lombardi Role of beta-adrenergic receptor gene polymorphisms in the long-term effects of beta-blockade with carvedilol in patients with chronic heart failure Cardiovasc Drugs Ther 24 2010 49 60
39. Beta-Blocker Evaluation of Survival Trial Investigators A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure N Engl J Med 344 2001 1659 1667
40. H.L. White, R.A. de Boer, A. Maqbool, D. Greenwood, D.J. van Veldhuisen, and R. Cuthbert An evaluation of the beta-1 adrenergic receptor Arg389Gly polymorphism in individuals with heart failure: a MERIT-HF sub-study Eur J Heart Fail 5 2003 463 468
41. MERIT-HF Investigators Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF) Lancet 353 1999 2001 2007
42. A.J. Sehnert, S.E. Daniels, M. Elashoff, J.A. Wingrove, C.R. Burrow, and B. Horne Lack of association between adrenergic receptor genotypes and survival in heart failure patients treated with carvedilol or metoprolol J Am Coll Cardiol 52 2008 644 651
43. M.R. Bristow, R. Ginsburg, V. Umans, M. Fowler, W. Minobe, and R. Rasmussen Beta 1- and beta 2-adrenergic-receptor subpopulations in nonfailing and failing human ventricular myocardium: coupling of both receptor subtypes to muscle contraction and selective beta 1-receptor down-regulation in heart failure Circ Res 59 1986 297 309
44. B.K. Kobilka, R.A. Dixon, T. Frielle, H.G. Dohlman, M.A. Bolanowski, and I.S. Sigal cDNA for the human beta 2-adrenergic receptor: a protein with multiple membrane-spanning domains and encoded by a gene whose chromosomal location is shared with that of the receptor for platelet-derived growth factor Proc Natl Acad Sci U S A 84 1987 46 50
45. S.A. Green, J. Turki, M. Innis, and S.B. Liggett Amino-terminal polymorphisms of the human beta 2-adrenergic receptor impart distinct agonist-promoted regulatory properties Biochemistry 33 1994 9414 9419
46. S.G. Terra, D.F. Pauly, C.R. Lee, J.H. Patterson, K.F. Adams, and R.S. Schofield beta-Adrenergic receptor polymorphisms and responses during titration of metoprolol controlled release/extended release in heart failure Clin Pharmacol Ther 77 2005 127 137
47. D.M. Kaye, B. Smirk, C. Williams, G. Jennings, M. Esler, and D. Holst Beta-adrenoceptor genotype influences the response to carvedilol in patients with congestive heart failure Pharmacogenetics 13 2003 379 382
48. S.A. Green, G. Cole, M. Jacinto, M. Innis, and S.B. Liggett A polymorphism of the human beta 2-adrenergic receptor within the fourth transmembrane domain alters ligand binding and functional properties of the receptor J Biol Chem 268 1993 23116 23121
49. M.D. Littlejohn, B.R. Palmer, A.M. Richards, C.M. Frampton, A.P. Pilbrow, and R.W. Troughton Ile164 variant of beta2-adrenoceptor does not influence outcome in heart failure but may interact with beta blocker treatment Eur J Heart Fail 10 2008 55 59
50. A. Neumeister, D.S. Charney, I. Belfer, M. Geraci, C. Holmes, and Y. Sharabi Sympathoneural and adrenomedullary functional effects of alpha2C-adrenoreceptor gene polymorphism in healthy humans Pharmacogenet Genomics 15 2005 143 149
51. M.T. Lobmeyer, Y. Gong, S.G. Terra, A.L. Beitelshees, T.Y. Langaee, and D.F. Pauly Synergistic polymorphisms of beta1 and alpha2C-adrenergic receptors and the influence on left ventricular ejection fraction response to beta-blocker therapy in heart failure Pharmacogenet Genomics 17 2007 277 282
52. M.R. Bristow, H. Krause-Steinrauf, R. Nuzzo, C.S. Liang, J. Lindenfeld, and B.D. Lowes Effect of baseline or changes in adrenergic activity on clinical outcomes in the beta-blocker evaluation of survival trial Circulation 110 2004 1437 1442
53. T.A. Kohout, and R.J. Lefkowitz Regulation of G protein-coupled receptor kinases and arrestins during receptor desensitization Mol Pharmacol 63 2003 9 18
54. S.B. Liggett, S. Cresci, R.J. Kelly, F.M. Syed, S.J. Matkovich, and H.S. Hahn A GRK5 polymorphism that inhibits beta-adrenergic receptor signaling is protective in heart failure Nat Med 14 2008 510 517
55. P.G. Shekelle, M.W. Rich, S.C. Morton, C.S. Atkinson, W. Tu, and M. Maglione Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials J Am Coll Cardiol 41 2003 1529 1538
56. B. Rigat, C. Hubert, F. Alhenc-Gelas, F. Cambien, P. Corvol, and F. Soubrier An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels J Clin Invest 86 1990 1343 1346
57. S.R. Holmer, C. Hengstenberg, B. Mayer, S. Engel, H. Lowel, and G.A. Riegger Marked suppression of renin levels by beta-receptor blocker in patients treated with standard heart failure therapy: a potential mechanism of benefit from beta-blockade J Intern Med 249 2001 167 172
58. M. Packer The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure J Am Coll Cardiol 20 1992 248 254
59. L. O'Toole, M. Stewart, P. Padfield, and K. Channer Effect of the insertion/deletion polymorphism of the angiotensin-converting enzyme gene on response to angiotensin-converting enzyme inhibitors in patients with heart failure J Cardiovasc Pharmacol 32 1998 988 994
60. M. Cicoira, L. Zanolla, A. Rossi, G. Golia, L. Franceschini, and G. Cabrini Failure of aldosterone suppression despite angiotensin-converting enzyme (ACE) inhibitor administration in chronic heart failure is associated with ACE DD genotype J Am Coll Cardiol 37 2001 1808 1812
61. W.H. Tang, R.H. Vagelos, Y.G. Yee, and M.B. Fowler Impact of angiotensin-converting enzyme gene polymorphism on neurohormonal responses to high- versus low-dose enalapril in advanced heart failure Am Heart J 148 2004 889 894
62. A.D. Tiago, D. Badenhorst, D. Skudicky, A.J. Woodiwiss, G.P. Candy, and R. Brooksbank An aldosterone synthase gene variant is associated with improvement in left ventricular ejection fraction in dilated cardiomyopathy Cardiovasc Res 54 2002 584 589
63. M.A. Cuoco, A.C. Pereira, F. Mota Gde, J.E. Krieger, and A.J. Mansur Genetic polymorphism, medical therapy and sequential cardiac function in patients with heart failure Arq Bras Cardiol 90 2008 252 256
64. C.K. Wu, J.L. Luo, C.T. Tsai, Y.T. Huang, C.L. Cheng, and J.K. Lee Demonstrating the pharmacogenetic effects of angiotensin-converting enzyme inhibitors on long-term prognosis of diastolic heart failure Pharmacogenomics J 10 2010 46 53
65. A. Muthumala, F. Drenos, P.M. Elliott, and S.E. Humphries Role of beta adrenergic receptor polymorphisms in heart failure: systematic review and meta-analysis Eur J Heart Fail 10 2008 3 13
66. L.M. Baudhuin, W.L. Miller, L. Train, S. Bryant, K.A. Hartman, and M. Phelps Relation of ADRB1, CYP2D6, and UGT1A1 polymorphisms with dose of, and response to, carvedilol or metoprolol therapy in patients with chronic heart failure Am J Cardiol 106 2010 402 408
67. M. Petersen, J.T. Andersen, B.R. Hjelvang, K. Broedbaek, S. Afzal, and M. Nyegaard Association of beta-adrenergic receptor polymorphisms and mortality in carvedilol-treated chronic heart-failure patients Br J Clin Pharmacol 71 2011 556 565
68. I. Johansson, E. Lundqvist, L. Bertilsson, M.L. Dahl, F. Sjoqvist, and M. Ingelman-Sundberg Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine Proc Natl Acad Sci U S A 90 1993 11825 11829
69. P. Zill, R. Engel, T.C. Baghai, G. Juckel, T. Frodl, and F. Muller-Siecheneder Identification of a naturally occurring polymorphism in the promoter region of the norepinephrine transporter and analysis in major depression Neuropsychopharmacology 26 2002 489 493
70. Y. Takekuma, T. Takenaka, M. Kiyokawa, K. Yamazaki, H. Okamoto, and A. Kitabatake Contribution of polymorphisms in UDP-glucuronosyltransferase and CYP2D6 to the individual variation in disposition of carvedilol J Pharm Pharm Sci 9 2006 101 112
71. D.E. Lanfear, S. Marsh, S. Cresci, J.A. Spertus, and H.L. McLeod Frequency of compound genotypes associated with beta-blocker efficacy in congestive heart failure Pharmacogenomics 5 2004 553 558
72. D. Kurnik, A. Cunningham, G. Sofowora, U. Kohli, C. Li, and E. Friedman GRK5 Gln41Leu polymorphism is not associated with sensitivity to beta(1)-adrenergic blockade in humans Pharmacogenomics 10 2009 1581 1587
73. T.J. Maxwell Beta-2 adrenergic receptor genotypes and haplotypes in different ethnic groups Int J Mol Med 16 2005 573 580
74. A.J. Woodiwiss, D. Badenhorst, K. Sliwa, R. Brooksbank, R. Essop, and P. Sareli Beta1- and alpha2c-adrenoreceptor variants as predictors of clinical aspects of dilated cardiomyopathy in people of African ancestry Cardiovasc J Afr 19 2008 188 193
75. D. Badenhorst, G.R. Norton, K. Sliwa, R. Brooksbank, R. Essop, and P. Sareli Impact of beta2-adrenoreceptor gene variants on cardiac cavity size and systolic function in idiopathic dilated cardiomyopathy Pharmacogenomics J 7 2007 339 345
76. E. Brand, N. Chatelain, F. Paillard, L. Tiret, S. Visvikis, and M. Lathrop Detection of putative functional angiotensinogen (AGT) gene variants controlling plasma AGT levels by combined segregation-linkage analysis Eur J Hum Genet 10 2002 715 723
77. X. Jeunemaitre, F. Soubrier, Y.V. Kotelevtsev, R.P. Lifton, C.S. Williams, and A. Charru Molecular basis of human hypertension: role of angiotensinogen Cell 71 1992 169 180
78. P.P. van Geel, Y.M. Pinto, A.A. Voors, H. Buikema, M. Oosterga, and H.J. Crijns Angiotensin II type 1 receptor A1166C gene polymorphism is associated with an increased response to angiotensin II in human arteries Hypertension 35 2000 717 721
79. W. Spiering, A.A. Kroon, M.M. Fuss-Lejeune, M.J. Daemen, and P.W. de Leeuw Angiotensin II sensitivity is associated with the angiotensin II type 1 receptor A(1166)C polymorphism in essential hypertensives on a high sodium diet Hypertension 36 2000 411 416
80. L. Pojoga, S. Gautier, H. Blanc, T.T. Guyene, O. Poirier, and F. Cambien Genetic determination of plasma aldosterone levels in essential hypertension Am J Hypertens 11 1998 856 860
81. A.G. Wilson, J.A. Symons, T.L. McDowell, H.O. McDevitt, and G.W. Duff Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation Proc Natl Acad Sci U S A 94 1997 3195 3199
82. R. Brooksbank, D. Badenhorst, K. Sliwa, G. Norton, and A. Woodiwiss The G-308A polymorphism of the TNF-alpha gene does not predict changes in cardiac function in response to medical therapy for idiopathic dilated cardiomyopathy Cardiovasc J Afr 19 2008 254 258